Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Nazli Dizman MD

Nazli Dizman MD

Resident, Internal Medicine, Yale School of Medicine, Yale New Haven Hospital, New Haven, Connecticut

Dr. Nazli Dizman is an internal medicine resident at Yale School of Medicine, Yale New Haven Hospital. Prior to joining Yale, she graduated from Ege University School of Medicine in Izmir, Turkey and completed her internal medicine residency training at Istanbul Medeniyet University School of Medicine in Istanbul, Turkey. She worked as a postdoctoral fellow in the Department of Medical Oncology and Therapeutics Research at City of Hope Comprehensive Cancer Center in Duarte, California between 2016 and 2020.

Dr. Dizman has been involved in clinical and translational research projects in the area of genitourinary cancers since 2016. She has played crucial roles in the planning, initiation and management of several clinical and translations studies examining the role of clinical factors, genomics, and the microbiome on clinical outcomes in genitourinary cancers. Dr. Dizman has published over 40 peer-reviewed articles in scientific journals and presented several abstracts at national and international meetings.

Disclosures

Consultation fees from Vivreon Gastroscience Inc.

Recent Contributions to PracticeUpdate:

  1. Clear Cell Renal Cell Carcinoma With Sarcomatoid Dedifferentiation in Patient With HIV
  2. Metastatic Renal Cell Carcinoma Patient With Indolent Disease
  3. Management of Rare RCC Subtypes—Chromophobe Renal Cell Carcinoma
  4. Management of Rare RCC Subtypes - Translocation RCC
  5. Management of Rare RCC Subtypes - Renal Medullary Carcinoma
  6. Systemic Therapy for mRCC Patient on Hemodialysis
  7. Genetics Consultation in RCC Patient
  8. ASCO: Cabozantinib and Atezolizumab in Urothelial Cancer
  9. ASCO: Early Data on the Gut Microbiome and Outcomes in RCC
  10. Progression After Immunotherapy in Patient With Recurrent RCC

Elsewhere

Most Read This Week

Recently Updated